Immunic says open-label extension data support durability of vidofludimus calcium disability outcomes in Phase 2 progressive MS trial

Immunic says open-label extension data support the durability of vidofludimus calcium disability outcomes in its Phase 2 progressive multiple sclerosis trial.

Detected & updated continuously · Source: Nebula